全文获取类型
收费全文 | 1396篇 |
免费 | 132篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 35篇 |
妇产科学 | 14篇 |
基础医学 | 203篇 |
口腔科学 | 24篇 |
临床医学 | 198篇 |
内科学 | 316篇 |
皮肤病学 | 40篇 |
神经病学 | 120篇 |
特种医学 | 72篇 |
外科学 | 187篇 |
综合类 | 11篇 |
预防医学 | 119篇 |
眼科学 | 29篇 |
药学 | 93篇 |
中国医学 | 3篇 |
肿瘤学 | 60篇 |
出版年
2023年 | 16篇 |
2022年 | 48篇 |
2021年 | 81篇 |
2020年 | 46篇 |
2019年 | 53篇 |
2018年 | 50篇 |
2017年 | 34篇 |
2016年 | 45篇 |
2015年 | 45篇 |
2014年 | 69篇 |
2013年 | 64篇 |
2012年 | 110篇 |
2011年 | 107篇 |
2010年 | 48篇 |
2009年 | 52篇 |
2008年 | 66篇 |
2007年 | 82篇 |
2006年 | 67篇 |
2005年 | 78篇 |
2004年 | 58篇 |
2003年 | 63篇 |
2002年 | 47篇 |
2001年 | 44篇 |
2000年 | 32篇 |
1999年 | 25篇 |
1998年 | 9篇 |
1997年 | 8篇 |
1996年 | 6篇 |
1995年 | 5篇 |
1994年 | 10篇 |
1993年 | 1篇 |
1992年 | 10篇 |
1991年 | 10篇 |
1990年 | 5篇 |
1989年 | 6篇 |
1988年 | 6篇 |
1987年 | 4篇 |
1986年 | 4篇 |
1985年 | 3篇 |
1984年 | 1篇 |
1983年 | 3篇 |
1981年 | 2篇 |
1980年 | 3篇 |
1979年 | 3篇 |
1977年 | 1篇 |
1975年 | 1篇 |
排序方式: 共有1531条查询结果,搜索用时 15 毫秒
61.
Pancreatic cancer is one of the most malignant cancers with a high mortality rate. Some types of pancreatic cancer cells overexpress epidermal growth factor receptor (EGFR), which is a potential target for anticancer agents. In this study, we examined the effect of epidermal growth factor (EGF)-conjugated liposomes containing curcumin (EGF-LP-Cur) on three different EGFR-expressed human pancreatic cancer cell lines, BxPC-3, Panc-1 and Mia Paca-2. We have demonstrated that it is feasible to prepare liposomal vesicles of EGF-LP-Cur and that it is stable in the liquid vehicle at ambient conditions for three weeks. In addition, the formulation of curcumin had higher cytotoxicity on BxPC-3 than on any other cells. It is also shown that the cellular uptake of curcumin on BxPC-3, which is essential for the cytotoxicity, is associated with EGFR-mediated mechanism of action. In summary, our results have showed that targeting EGFR with EGF-conjugated curcumin liposomes enhanced the antitumor activity of curcumin against human pancreatic cancer cells. 相似文献
62.
63.
Michael Mengel Alexandre Loupy Mark Haas Candice Roufosse Maarten Naesens Enver Akalin Marian C. Clahsen‐van Groningen Jessy Dagobert Anthony J. Demetris Jean‐Paul Duong van Huyen Juliette Gueguen Fadi Issa Blaise Robin Ivy Rosales Jan H. Von der Thüsen Alberto Sanchez‐Fueyo Rex N. Smith Kathryn Wood Benjamin Adam Robert B. Colvin 《American journal of transplantation》2020,20(9):2305-2317
64.
Robert Recker David Dempster Bente Langdahl Hilde Giezek Seth Clark Graham Ellis Tobias de Villiers Ivo Valter Cristiano AF Zerbini Dosinda Cohn Arthur Santora Le T Duong 《Journal of bone and mineral research》2020,35(7):1289-1299
Odanacatib (ODN), a selective oral inhibitor of cathepsin K, was an investigational agent previously in development for the treatment of osteoporosis. In this analysis, the effects of ODN on bone remodeling/modeling and structure were examined in the randomized, double-blind, placebo-controlled, event-driven, Phase 3, Long-term Odanacatib Fracture Trial (LOFT; NCT00529373) and planned double-blind extension in postmenopausal women with osteoporosis. A total of 386 transilial bone biopsies, obtained from consenting patients at baseline (ODN n = 17, placebo n = 23), month 24 (ODN n = 112, placebo n = 104), month 36 (ODN n = 42, placebo n = 41), and month 60 (ODN n = 27, placebo n = 20) were assessed by dynamic and static bone histomorphometry. Patient characteristics at baseline and BMD changes over 5 years for this subset were comparable to the overall LOFT population. Qualitative assessment of biopsies revealed no abnormalities. Consistent with the mechanism of ODN, osteoclast number was higher with ODN versus placebo over time. Regarding bone remodeling, dynamic bone formation indices in trabecular, intracortical, and endocortical surfaces were generally similar in ODN-treated versus placebo-treated patients after 2 years of treatment. Regarding periosteal modeling, the proportion of patients with periosteal double labels and the bone formation indices increased over time in the ODN-treated patients compared with placebo. This finding supported the observed numerical increase in cortical thickness at month 60 versus placebo. In conclusion, ODN treatment for 5 years did not reduce bone remodeling and increased the proportion of patients with periosteal bone formation. These results are consistent with the mechanism of action of ODN, and are associated with continued BMD increases and reduced risk of fractures compared with placebo in the LOFT Phase 3 fracture trial. © 2020 American Society for Bone and Mineral Research. 相似文献
65.
Inhibition of Cathepsin K Increases Modeling‐Based Bone Formation,and Improves Cortical Dimension and Strength in Adult Ovariectomized Monkeys 下载免费PDF全文
Brenda L Pennypacker Charles M Chen Helen Zheng Mei‐Shu Shih Mary Belfast Rana Samadfam Le T Duong 《Journal of bone and mineral research》2014,29(8):1847-1858
Treatment with the cathepsin K (CatK) inhibitor odanacatib (ODN) protects against bone loss and maintains normal biomechanical properties in the spine and hip of ovariectomized (OVX) preclinical models. Here, we characterized the effects of ODN on the dynamics of cortical modeling and remodeling, and dimension and strength of the central femur in adult OVX‐rhesus monkeys. Animals were treated with vehicle or ODN (6 or 30 mg/kg, once per day [q.d., p.o.]) in prevention mode for 21 months. Calcein and tetracycline double‐labeling were given at 12 and 21 months, and the femoral cross‐sections were subjected to dynamic histomorphometric and cement line analyses. ODN treatment significantly increased periosteal and endocortical bone formation (BFR/BS), accompanied with an increase in endocortical mineralizing surface (102%, p < 0.01) with the 6 mg/kg dose. ODN at both doses reduced remodeling hemiosteon numbers by 51% and 66% (p < 0.05), respectively, and ODN 30 mg/kg numerically reduced activation frequency without affecting wall thickness. On the same endocortical surface, ODN increased all modeling‐based parameters, while reducing intracortical remodeling, consistent with the observed no treatment effects on cortical porosity. ODN 30 mg/kg markedly increased cortical thickness (CtTh, p < 0.001) and reduced marrow area (p < 0.01). Lastly, ODN treatment increased femoral structural strength (p < 0.001). Peak load was positively correlated with the increases in bone mineral content (BMC) (r2 = 0.9057, p < 0.0001) and CtTh (r2 = 0.6866, p < 0.0001). Taken together, by reducing cortical remodeling‐based and stimulating modeling‐based bone formation, ODN significantly improved cortical dimension and strength in OVX monkeys. This novel mechanism of CatK inhibition in stimulating cortical formation suggests that ODN represents a novel therapeutic approach for the treatment of osteoporosis. © 2014 American Society for Bone and Mineral Research. 相似文献
66.
67.
Michel Duong Claudine Dubois Marielle Buisson Michelle Grappin Pascal Chavanet Henri Portier Jean Christophe Eicher 《Clinical cardiology》1997,20(5):497-502
A case of HIV-associated cardiac non-Hodgkin's lymphoma (NHL) is described, and the epidemiologic and clinicopathologic features of 21 cases previously reported in the literature are analyzed. All patients were homosexual males, and the cardiac NHL was the first acquired immune deficiency syndrome-defining condition in the majority. Patients were referred with nonspecific clinical findings including dyspnea and tachycardia, but rapid progression of cardiac dysfunction was frequent after symptoms appeared. Echocardiography constitutes the most useful noninvasive procedure in the diagnosis of cardiac NHL. Most of the patients had disseminated disease at initial presentation; pathologically, the lymphomas were of B lymphocyte origin and of high-grade subtypes. Prognosis of HIV-associated cardiac NHL is generally poor, although clinical remission has been observed with combination chemotherapy. Cardiac lymphomas in HIV-associated patients are typically high-grade and often disseminate early. Although the prognosis is poor, patients in whom dissemination has not occurred could have longer survival under systemic chemotherapy. 相似文献
68.
Nguyen Van Hong Alfred Amambua-Ngwa Nguyen Quang Tuan Do Duy Cuong Nguyen Thi Huong Giang Nguyen Van Dung Ta Thi Tinh Nguyen Van Tien Bui Quang Phuc Tran Thanh Duong Anna Rosanas-Urgell Umberto D’Alessandro Jean-Pierre Van Geertruyden Annette Erhart 《Emerging infectious diseases》2014,20(7):1207-1210
Resistance to artemisinin derivatives, the most potent antimalarial drugs currently used, has emerged in Southeast Asia and threatens to spread to Africa. We report a case of malaria in a man who returned to Vietnam after 3 years in Angola that did not respond to intravenous artesunate and clindamycin or an oral artemisinin-based combination. 相似文献
69.
Duong Duc Pham BonCho Ku Chol Shin Nam H. Cho Seongwon Cha Jong Yeol Kim 《Diabetes research and clinical practice》2014